EUCTR2014-002372-89-BE进行中（未招募）1 期
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological or cytological confirmed SCLC
- •Performance Status 0-1
- •Adequate organ function
- •Measurable disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 85
排除标准
- •Known or suspected brain metastasis
- •Small cell cancer not lung in origin
- •Significant or acute medical illness
- •Uncontrolled or significant cardiac disease
- •Infection
- •> Grade 2 peripheral neuropathy
- •Concomitant malignancies
- •HIV related disease or known or suspected HIV+
- •Hepatitis B or C infection
- •ECG abnormalities as defined by the protocol
- •Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine
研究者
相似试验
已完成
不适用
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed / Refractory Small Cell Lung Cancer (CA001-030)small cell lung cancerneoplasms in the lungNL-OMON43272Bristol-Myers Squibb6
进行中（未招募）
1 期
BMS-986012 in Relapsed/Refractory SCLCMedDRA version: 18.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864Small Cell Lung CancerEUCTR2014-002372-89-NLBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-000603-91-NLBristol-Myers Squibb International Corporation204
已完成
不适用
A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumorsall solid tumors in part 1 and only NSCLC, RCC, CRPC, SCCHN, melanoma and pancreatic cancer in part 2.advanced solid tumorscancerNL-OMON47607Bristol-Myers Squibb15
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-PLBristol-Myers Squibb International Corporation907